Autoimmune diseases are a diverse group of conditions characterized by aberrant B cell
and T cell reactivity to normal constituents of the host. These diseases occur widely and …

In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …

B cells and the antibodies they produce have a deeply penetrating influence on human
physiology. Here, we review current understanding of how B cell responses are initiated; the …

The failure of anti-CD20 antibody (Rituximab) as therapy for lupus may be attributed to the
transient and incomplete B cell depletion achieved in clinical trials. Here, using an …

Objective To compare response to rituximab (RTX) between adult patients positive for
myelin oligodendrocyte glycoprotein (MOG) and aquaporin‐4 (AQP4) antibodies. Methods …

Heterozygous signal transducer and activator of transcription 1 (STAT1) gain-of-function
(GOF) mutations promote a clinical syndrome of immune dysregulation characterized by …

Given the global surge in autoimmune diseases, it is critical to evaluate emerging
therapeutic interventions. Despite numerous new targeted immunomodulatory therapies …

Purpose of review FDA-approved B cell-targeted therapy has expanded to a multitude of
autoimmune diseases ranging from organ specific diseases, like pemphigus and multiple …

Autoimmune diseases with B cell–directed therapeutics approved by the US Food and Drug
Administration are surprisingly diverse in clinical manifestations and pathophysiology. In this …

Class-switched antibodies to double-stranded DNA (dsDNA) are prevalent and pathogenic
in systemic lupus erythematosus (SLE), yet mechanisms of their development remain poorly …